José Marie Orellana

Learn More
BACKGROUND The effects of cinacalcet in persistent and/or hypercalcaemia-associated secondary hyperparathyroidism (SHPT) have been described in patients on dialysis. OBJECTIVES To evaluate the efficacy and safety of cinacalcet in SHPT not on dialysis and its effects on bone turnover markers. METHODS Non-randomised, longitudinal, observational,(More)